Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie G Markgraf

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Pharmacological and Toxicological Methods|June 16, 2010
Comparison of methods for analysis of functional observation battery (FOB) dataCarrie G Markgraf, Maria Cirino, John Meredith
Journal of Pharmacological and Toxicological Methods|July 12, 2005
Validation of a motor activity system by a robotically controlled vehicle and using standard reference compoundsJohn P Patterson, Carrie G Markgraf, Maria Cirino, et al.
Journal of Pharmacological and Toxicological Methods|August 25, 2014
Assessment of seizure liability of Org 306039, a 5-HT2c agonist, using hippocampal brain slice and rodent EEG telemetryCarrie G Markgraf, Erik DeBoer, Jin Zhai, et al.
Regulatory Toxicology and Pharmacology : RTP|December 5, 2017
Abuse liability assessment for biologic drugs - All molecules are not created equalChristina L Zuch de Zafra, Carrie G Markgraf, David R Compton, et al.
Journal of Pharmacological and Toxicological Methods|August 18, 2020
Twenty years of safety pharmacology model validation and the wider implications of this to drug discoveryMichael K Pugsley, Bisrat Bekele, Helene Griessel, et al.
Journal of Pharmacological and Toxicological Methods|August 12, 2017
The Safety Pharmacology Society salary surveyMichael K Pugsley, Simon Authier, Tiffini Brabham, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2021
Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase ActivityDianne K Bryce, Chris M Ware, Janice D Woodhouse, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 27, 2015
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew J Fell, Christian Mirescu, Kallol Basu, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Pharmacological and Toxicological Methods|June 16, 2010
Comparison of methods for analysis of functional observation battery (FOB) dataCarrie G Markgraf, Maria Cirino, John Meredith
Journal of Pharmacological and Toxicological Methods|July 12, 2005
Validation of a motor activity system by a robotically controlled vehicle and using standard reference compoundsJohn P Patterson, Carrie G Markgraf, Maria Cirino, et al.
Journal of Pharmacological and Toxicological Methods|August 25, 2014
Assessment of seizure liability of Org 306039, a 5-HT2c agonist, using hippocampal brain slice and rodent EEG telemetryCarrie G Markgraf, Erik DeBoer, Jin Zhai, et al.
Regulatory Toxicology and Pharmacology : RTP|December 5, 2017
Abuse liability assessment for biologic drugs - All molecules are not created equalChristina L Zuch de Zafra, Carrie G Markgraf, David R Compton, et al.
Journal of Pharmacological and Toxicological Methods|August 18, 2020
Twenty years of safety pharmacology model validation and the wider implications of this to drug discoveryMichael K Pugsley, Bisrat Bekele, Helene Griessel, et al.
Journal of Pharmacological and Toxicological Methods|August 12, 2017
The Safety Pharmacology Society salary surveyMichael K Pugsley, Simon Authier, Tiffini Brabham, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2021
Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase ActivityDianne K Bryce, Chris M Ware, Janice D Woodhouse, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 27, 2015
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew J Fell, Christian Mirescu, Kallol Basu, et al.
Pageof 1